SERES THERAPEUTICS INC (MCRB) Stock Price, Quote, News and Overview
NASDAQ:MCRB - Nasdaq - US81750R1023 - Common Stock - Currency: USD
MCRB Quote, Performance and Key Statistics
0.37
-0.03 (-7.48%)
The current stock price of MCRB is 0.37 USD. In the past month the price decreased by -49.45%. In the past year, price decreased by -33.92%.
MCRB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About MCRB
Company Profile
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 233 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The firm is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The firm's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.
Company Info
SERES THERAPEUTICS INC
101 Cambridge Park Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Eric D. Shaff
Employees: 233
Company Website: https://www.serestherapeutics.com/
Investor Relations: https://ir.serestherapeutics.com
Phone: 16179459626
SERES THERAPEUTICS INC / MCRB FAQ
What is the stock price of SERES THERAPEUTICS INC today?
The current stock price of MCRB is 0.37 USD. The price decreased by -7.48% in the last trading session.
What is the ticker symbol for SERES THERAPEUTICS INC stock?
The exchange symbol of SERES THERAPEUTICS INC is MCRB and it is listed on the Nasdaq exchange.
On which exchange is MCRB stock listed?
MCRB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SERES THERAPEUTICS INC stock?
13 analysts have analysed MCRB and the average price target is 3.9 USD. This implies a price increase of 954.18% is expected in the next year compared to the current price of 0.37. Check the SERES THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SERES THERAPEUTICS INC worth?
SERES THERAPEUTICS INC (MCRB) has a market capitalization of 64.51M USD. This makes MCRB a Micro Cap stock.
How many employees does SERES THERAPEUTICS INC have?
SERES THERAPEUTICS INC (MCRB) currently has 233 employees.
What are the support and resistance levels for SERES THERAPEUTICS INC (MCRB) stock?
SERES THERAPEUTICS INC (MCRB) has a resistance level at 0.64. Check the full technical report for a detailed analysis of MCRB support and resistance levels.
Should I buy SERES THERAPEUTICS INC (MCRB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MCRB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MCRB, evaluating the profitability, health, valuation and growth aspects
- SERES THERAPEUTICS INC (MCRB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SERES THERAPEUTICS INC (MCRB) Sales and EPS estimates to see what analysts future expectations are.
- SERES THERAPEUTICS INC (MCRB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SERES THERAPEUTICS INC (MCRB) Insider and Institutional Ownership to learn about the owners and their transactions.
- SERES THERAPEUTICS INC (MCRB) Stock Chart to make your own analysis
- SERES THERAPEUTICS INC (MCRB) Latest news and press-releases to stay up to date.
Does SERES THERAPEUTICS INC (MCRB) stock pay dividends?
MCRB does not pay a dividend.
When does SERES THERAPEUTICS INC (MCRB) report earnings?
SERES THERAPEUTICS INC (MCRB) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of SERES THERAPEUTICS INC (MCRB)?
SERES THERAPEUTICS INC (MCRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.97).
What is the Short Interest ratio of SERES THERAPEUTICS INC (MCRB) stock?
The outstanding short interest for SERES THERAPEUTICS INC (MCRB) is 11.65% of its float. Check the ownership tab for more information on the MCRB short interest.
MCRB Technical Analysis
MCRB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MCRB. While MCRB seems to be doing ok healthwise, there are quite some concerns on its profitability.
MCRB Financial Highlights
Over the last trailing twelve months MCRB reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS decreased by -7.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.25% | ||
| ROE | -106.51% | ||
| Debt/Equity | 0 |
MCRB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to MCRB. The Buy consensus is the average rating of analysts ratings from 13 analysts.